Hydroxyamphetamine

Identification

Name
Hydroxyamphetamine
Accession Number
DB09352
Type
Small Molecule
Groups
Approved
Description

Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test. Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary stinging in the eyes. The main use of hydroxyamphetamines as eye drops is the diagnosis of Horner's syndrome which is characterized by nerve lesions.

Structure
Thumb
Synonyms
  • 4-(2-aminopropyl)phenol
  • 4-hydroxyamphetamine
  • dl-4-hydroxyamphetamine
  • dl-p-hydroxyamphetamine
  • Hydroxyamphetamine
  • p-hydroxyamphetamine
External IDs
NSC-170995
Product Ingredients
IngredientUNIICASInChI Key
Hydroxyamfetamine hydrobromide59IG47SZ0E306-21-8RZCJLMTXBMNRAD-UHFFFAOYSA-N
International/Other Brands
Norveritol / Pulsoton
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ParemydHydroxyamfetamine hydrobromide (10 mg/mL) + Tropicamide (2.5 mg/mL)SolutionOphthalmicAkorn1992-01-30Not applicableUs
Categories
UNII
FQR280JW2N
CAS number
103-86-6
Weight
Average: 151.2056
Monoisotopic: 151.099714043
Chemical Formula
C9H13NO
InChI Key
GIKNHHRFLCDOEU-UHFFFAOYSA-N
InChI
InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3
IUPAC Name
4-(2-aminopropyl)phenol
SMILES
CC(N)CC1=CC=C(O)C=C1

Pharmacology

Indication

Mydriatic agent (eye pupil dilatation) for diagnosis of ophthalmic nerve lesions.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Hydroxyamphetamine hydrobromide is an indirect acting sympathomimetic agent which causes the release of norepinephrine from adrenergic nerve terminals, resulting in mydriasis.

Absorption

Intended for local use only (ophthalmic use).

Volume of distribution

Intended for local use only (ophthalmic use).

Protein binding

Intended for local use only (ophthalmic use).

Metabolism

Intended for local use only (ophthalmic use).

Route of elimination

Intended for local use only (ophthalmic use).

Half life
Not Available
Clearance

Intended for local use only (ophthalmic use).

Toxicity

No data available.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Hydroxyamphetamine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Hydroxyamphetamine.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
AcrivastineHydroxyamphetamine may decrease the sedative activities of Acrivastine.Approved
AlcaftadineHydroxyamphetamine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilHydroxyamphetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlimemazineHydroxyamphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmasilateAlmasilate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved, Experimental
AloglutamolAloglutamol may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Experimental
AlphacetylmethadolHydroxyamphetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineHydroxyamphetamine may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of Hydroxyamphetamine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of Hydroxyamphetamine.Approved
Ammonium chlorideThe serum concentration of Hydroxyamphetamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmoxapineAmoxapine may increase the stimulatory activities of Hydroxyamphetamine.Approved
AmperozideAmperozide may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Hydroxyamphetamine.Approved, Illicit
AntazolineHydroxyamphetamine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
AstemizoleHydroxyamphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtomoxetineAtomoxetine may increase the hypertensive activities of Hydroxyamphetamine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Hydroxyamphetamine.Investigational, Vet Approved
AzatadineHydroxyamphetamine may decrease the sedative activities of Azatadine.Approved
AzelastineHydroxyamphetamine may decrease the sedative activities of Azelastine.Approved
BamipineHydroxyamphetamine may decrease the sedative activities of Bamipine.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Hydroxyamphetamine.Investigational
BenzatropineHydroxyamphetamine may decrease the sedative activities of Benzatropine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Hydroxyamphetamine.Approved, Illicit
BezitramideHydroxyamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Hydroxyamphetamine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Experimental
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Hydroxyamphetamine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Brofaromine.Experimental
BromperidolBromperidol may decrease the stimulatory activities of Hydroxyamphetamine.Investigational
BrompheniramineHydroxyamphetamine may decrease the sedative activities of Brompheniramine.Approved
BucindololThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Bucindolol.Investigational
BuclizineHydroxyamphetamine may decrease the sedative activities of Buclizine.Approved
BuprenorphineHydroxyamphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
ButorphanolHydroxyamphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric AcidHydroxyamphetamine may decrease the sedative activities of Butyric Acid.Experimental, Investigational
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Experimental
CarbinoxamineHydroxyamphetamine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilHydroxyamphetamine may increase the analgesic activities of Carfentanil.Illicit, Investigational, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Hydroxyamphetamine.Approved, Investigational
CetirizineHydroxyamphetamine may decrease the sedative activities of Cetirizine.Approved
ChloropyramineHydroxyamphetamine may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineHydroxyamphetamine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineHydroxyamphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Hydroxyamphetamine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational, Withdrawn
CimetidineHydroxyamphetamine may decrease the sedative activities of Cimetidine.Approved
CinnarizineHydroxyamphetamine may decrease the sedative activities of Cinnarizine.Approved, Investigational
ClemastineHydroxyamphetamine may decrease the sedative activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Hydroxyamphetamine.Approved, Investigational, Vet Approved
ClomipramineClomipramine may increase the stimulatory activities of Hydroxyamphetamine.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
ClozapineClozapine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
CodeineHydroxyamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
CyclizineHydroxyamphetamine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Hydroxyamphetamine.Approved
CyproheptadineHydroxyamphetamine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Hydroxyamphetamine.Approved
DesipramineDesipramine may increase the stimulatory activities of Hydroxyamphetamine.Approved
DesloratadineHydroxyamphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
DexbrompheniramineHydroxyamphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniramineHydroxyamphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateHydroxyamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideHydroxyamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneHydroxyamphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineHydroxyamphetamine may increase the analgesic activities of Dezocine.Approved, Investigational
DibenzepinDibenzepin may increase the stimulatory activities of Hydroxyamphetamine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
DihydrocodeineHydroxyamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineHydroxyamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineHydroxyamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateHydroxyamphetamine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneHydroxyamphetamine may decrease the sedative activities of Dimetindene.Approved, Investigational
DimetotiazineHydroxyamphetamine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineHydroxyamphetamine may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylateHydroxyamphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Hydroxyamphetamine.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Hydroxyamphetamine.Approved
DosulepinDosulepin may increase the stimulatory activities of Hydroxyamphetamine.Approved
DoxepinHydroxyamphetamine may decrease the sedative activities of Doxepin.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Doxofylline.Approved
DoxylamineHydroxyamphetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEHydroxyamphetamine may increase the analgesic activities of DPDPE.Experimental
DronabinolDronabinol may increase the tachycardic activities of Hydroxyamphetamine.Approved, Illicit
DroperidolDroperidol may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Vet Approved
EbastineHydroxyamphetamine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Hydroxyamphetamine.Investigational
EmedastineHydroxyamphetamine may decrease the sedative activities of Emedastine.Approved
EpanololThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Hydroxyamphetamine.Approved
EpinastineHydroxyamphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Hydroxyamphetamine.Approved, Vet Approved
EsmirtazapineHydroxyamphetamine may decrease the sedative activities of Esmirtazapine.Investigational
EthopropazineHydroxyamphetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Hydroxyamphetamine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Withdrawn
EthylmorphineHydroxyamphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Etilefrine is combined with Hydroxyamphetamine.Withdrawn
EtorphineHydroxyamphetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineHydroxyamphetamine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Hydroxyamphetamine.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Fenozolone.Experimental
FentanylHydroxyamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineHydroxyamphetamine may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
FlunarizineHydroxyamphetamine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Hydroxyamphetamine.Approved, Investigational, Vet Approved
Glutamic AcidThe serum concentration of Hydroxyamphetamine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of Hydroxyamphetamine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HarmalineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Harmaline.Experimental
HeroinHydroxyamphetamine may increase the analgesic activities of Heroin.Approved, Illicit, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Hydroxyamphetamine.Experimental
HydrocodoneHydroxyamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneHydroxyamphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Experimental, Investigational
HydroxyzineHydroxyamphetamine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
ImipramineImipramine may increase the stimulatory activities of Hydroxyamphetamine.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Hydroxyamphetamine.Approved, Investigational
Ioflupane I-123Hydroxyamphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of Hydroxyamphetamine.Experimental
IproclozideIproclozide may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Hydroxyamphetamine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Hydroxyamphetamine.Approved
IsothipendylHydroxyamphetamine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Hydroxyamphetamine.Approved, Withdrawn
KetobemidoneHydroxyamphetamine may increase the analgesic activities of Ketobemidone.Approved, Investigational
KetotifenHydroxyamphetamine may decrease the sedative activities of Ketotifen.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Hydroxyamphetamine.Approved
LafutidineHydroxyamphetamine may decrease the sedative activities of Lafutidine.Investigational
LavoltidineHydroxyamphetamine may decrease the sedative activities of Lavoltidine.Investigational
LevocabastineHydroxyamphetamine may decrease the sedative activities of Levocabastine.Approved
LevocetirizineHydroxyamphetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateHydroxyamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
LevorphanolHydroxyamphetamine may increase the analgesic activities of Levorphanol.Approved
LinezolidLinezolid may increase the hypertensive activities of Hydroxyamphetamine.Approved, Investigational
LithiumLithium may decrease the stimulatory activities of Hydroxyamphetamine.Approved
LodoxamideHydroxyamphetamine may decrease the sedative activities of Lodoxamide.Approved
LofentanilHydroxyamphetamine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of Hydroxyamphetamine.Experimental
LoratadineHydroxyamphetamine may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
MeclizineHydroxyamphetamine may decrease the sedative activities of Meclizine.Approved
MefenorexThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Mefenorex.Experimental
MelperoneMelperone may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Hydroxyamphetamine.Approved
MeptazinolHydroxyamphetamine may increase the analgesic activities of Meptazinol.Experimental
MepyramineHydroxyamphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineHydroxyamphetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Hydroxyamphetamine.Approved, Investigational
MethadoneHydroxyamphetamine may increase the analgesic activities of Methadone.Approved
Methadyl AcetateHydroxyamphetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Hydroxyamphetamine.Approved, Illicit
MethapyrileneHydroxyamphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
MethenamineThe serum concentration of Hydroxyamphetamine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Hydroxyamphetamine.Approved, Investigational
Methylene blueMethylene blue may increase the hypertensive activities of Hydroxyamphetamine.Approved, Investigational
MetiamideHydroxyamphetamine may decrease the sedative activities of Metiamide.Experimental
MianserinHydroxyamphetamine may decrease the sedative activities of Mianserin.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Hydroxyamphetamine.Approved
MinaprineMinaprine may increase the hypertensive activities of Hydroxyamphetamine.Approved
MirtazapineHydroxyamphetamine may decrease the sedative activities of Mirtazapine.Approved
MizolastineHydroxyamphetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Hydroxyamphetamine.Approved
MolindoneMolindone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
MoperoneMoperone may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
MorphineHydroxyamphetamine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
NabiloneNabilone may increase the tachycardic activities of Hydroxyamphetamine.Approved, Investigational
NalbuphineHydroxyamphetamine may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
NicomorphineHydroxyamphetamine may increase the analgesic activities of Nicomorphine.Experimental
NizatidineHydroxyamphetamine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Hydroxyamphetamine.Approved
NormethadoneHydroxyamphetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of Hydroxyamphetamine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Hydroxyamphetamine.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
OlopatadineHydroxyamphetamine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Hydroxyamphetamine.Approved
OpipramolOpipramol may increase the stimulatory activities of Hydroxyamphetamine.Investigational
OpiumHydroxyamphetamine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Hydroxyamphetamine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Hydroxyamphetamine.Investigational
OxatomideHydroxyamphetamine may decrease the sedative activities of Oxatomide.Investigational
OxycodoneHydroxyamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Hydroxyamphetamine.Approved
OxymorphoneHydroxyamphetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
OzagrelHydroxyamphetamine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
PargylinePargyline may increase the hypertensive activities of Hydroxyamphetamine.Approved
PemirolastHydroxyamphetamine may decrease the sedative activities of Pemirolast.Approved, Investigational
PenfluridolPenfluridol may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
PentazocineHydroxyamphetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Hydroxyamphetamine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
PethidineHydroxyamphetamine may increase the analgesic activities of Pethidine.Approved
PhenazocineHydroxyamphetamine may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Hydroxyamphetamine.Approved
PhenindamineHydroxyamphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
PheniramineHydroxyamphetamine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Hydroxyamphetamine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Hydroxyamphetamine.Approved
PhenoperidineHydroxyamphetamine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Hydroxyamphetamine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Hydroxyamphetamine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Hydroxyamphetamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Hydroxyamphetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Hydroxyamphetamine.Approved
PipamperonePipamperone may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
PipotiazinePipotiazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
PiritramideHydroxyamphetamine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Hydroxyamphetamine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
PrenalterolThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Prenalterol.Experimental
ProcarbazineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Hydroxyamphetamine.Approved, Investigational
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Vet Approved
PromethazineHydroxyamphetamine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Hydroxyamphetamine.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Hydroxyamphetamine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Pseudoephedrine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
QuifenadineHydroxyamphetamine may decrease the sedative activities of Quifenadine.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Hydroxyamphetamine.Investigational
RanitidineHydroxyamphetamine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Hydroxyamphetamine.Approved
RemifentanilHydroxyamphetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
RisperidoneRisperidone may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Hydroxyamphetamine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Hydroxyamphetamine.Approved, Investigational
Roxatidine acetateHydroxyamphetamine may decrease the sedative activities of Roxatidine acetate.Approved, Investigational
SafrazineSafrazine may increase the hypertensive activities of Hydroxyamphetamine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational, Withdrawn
Sodium bicarbonateSodium bicarbonate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
SufentanilHydroxyamphetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
SultoprideSultopride may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Synephrine is combined with Hydroxyamphetamine.Experimental
TapentadolHydroxyamphetamine may increase the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Hydroxyamphetamine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Hydroxyamphetamine.Approved
TerfenadineHydroxyamphetamine may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifeneHydroxyamphetamine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Hydroxyamphetamine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Hydroxyamphetamine.Approved
ThiopropazateThiopropazate may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Hydroxyamphetamine.Approved
ThonzylamineHydroxyamphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
TiaprideTiapride may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
TilidineHydroxyamphetamine may increase the analgesic activities of Tilidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Hydroxyamphetamine.Approved
TramadolHydroxyamphetamine may increase the analgesic activities of Tramadol.Approved, Investigational
TramazolineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Tramazoline.Investigational
TranilastHydroxyamphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Hydroxyamphetamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Hydroxyamphetamine.Approved
TretoquinolThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Tretoquinol.Experimental
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of Hydroxyamphetamine.Approved
TripelennamineHydroxyamphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineHydroxyamphetamine may decrease the sedative activities of Triprolidine.Approved
TritoqualineHydroxyamphetamine may decrease the sedative activities of Tritoqualine.Experimental
TromethamineTromethamine may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
TyramineThe risk or severity of adverse effects can be increased when Tyramine is combined with Hydroxyamphetamine.Investigational, Nutraceutical
VeraliprideVeralipride may decrease the stimulatory activities of Hydroxyamphetamine.Experimental
Vitamin CThe serum concentration of Hydroxyamphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
ZotepineZotepine may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Hydroxyamphetamine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. product info [Link]
  2. article [Link]
  3. product info [Link]
External Links
Human Metabolome Database
HMDB60765
PubChem Compound
3651
PubChem Substance
347827833
ChemSpider
3525
BindingDB
81459
ChEBI
103855
ChEMBL
CHEMBL1546
Wikipedia
4-Hydroxyamphetamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.13 mg/mLALOGPS
logP0.58ALOGPS
logP1ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)10.48ChemAxon
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area46.25 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity45.69 m3·mol-1ChemAxon
Polarizability17.17 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Organopnictogen compounds / Organooxygen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Amphetamine or derivatives / Phenylpropane / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Phenol / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Primary amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on November 30, 2015 12:10 / Updated on December 01, 2017 17:29